Jacobson Pharma Launches Smartfish Health Nutrition Products from Norway in Greater China and Asia Pacific Region
HONG KONG, Nov 12, 2019 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines, announced the launch of Smartfish's health nutrition range of products in Greater China (including Mainland China, Hong Kong, Macau and Taiwan) and Asia under an exclusive distribution agreement with Smartfish AS, a branded health nutrition company incorporated in Norway.
|Photo Caption (1): Smartfish products for the consumer health nutrition range; Photo Caption (2): Smartfish is the official supplier of sports nutrition drinks to sports clubs and national teams, including English Premier League Tottenham Hotspurs Football Club|
According to the agreement, the Group has an in-licensed right for 10 years to distribute and market Smartfish's consumer health products in Greater China and the Asia Pacific Region, covering four product ranges, namely "Smartfish Recharge" for sports nutrition, "Smartfish Resolve" for improving metabolic health and diabetes care, "Smartfish Reflect" for promoting adults' brain health and cognitive function, and "Smartfish Cream" for benefiting children's brain development
Built upon a patented emulsion technology and clinically substantiated, Smartfish's Omega-3-enhanced nutritional drinks and emulsion products complement the fast-growing medical and consumer nutrition markets with products of evidence-based health benefits.
Differentiated from standard fish oil supplements, Smartfish's emulsion carries high levels of Omega 3 fatty acids, in synergy with other nutrients, that can produce the potentiating anti-inflammatory effects to deliver various health benefits . It can also ensure a tasty delivery of nutrients by protecting Omega-3 fatty acids, which are rich in fish oil, from oxidizing and forming the rancid taste. The products are clinically tested, and all health benefit claims for Smartfish products are supported by rigorous science.
Smartfish's products range provides health nutrition for the elderly and the young, medical nutrition for chronic disease patients, and sports nutrition for athletes. Smartfish has established itself as a trusted nutritional source for professional athletes worldwide being the official supplier of sports nutrition drinks to sports clubs and national teams, which include English Premier League Tottenham Hotspurs Football Club and Norwegian Nordic Combined National Team of Skiing.
Jacobson Pharma's strategic collaboration with Smartfish also included a shareholding investment of 9.04% of Smartfish's issued capital made in July 2019, which is expected to forge a stronger partnership and platform for both companies on exploring potential business cooperation in the high growing consumer health nutrition market in the future.
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, comments, "We welcome Smartfish's nutrition products with well-documented potency to our consumer health product portfolio. The health nutrition market has witnessed strong growth driven by the greater inclination towards self-care and health problems prevention, alongside a growing aged population and increase in disposable income. Through this collaboration, Jacobson Pharma has primed itself to collaborate with Smartfish in exploiting the latent demand for clinically substantiated health nutrition products to meet different lifestyle and healthcare needs among consumers in Greater China and the Asia Pacific Region."
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group's proprietary brand portfolio, notably being Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Flying Eagle Wood Lok Medicated Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. The Group aims to enrich its portfolio through addition of high value-added products covering sterile injections, oncology products as well as orphan drugs and biosimilars. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
About Smartfish AS
Smartfish is a company incorporated in Norway which focuses on research & development, production and marketing of advanced, science-based and clinically documented nutritional products. Smartfish provides unique nutritional solutions for both medical use and consumer health. Its nutrition products are based on a proprietary emulsion technology that enables the effective delivery of high levels of Omega 3 fatty acids, whey protein and other nutrients. Smartfish has a number of ongoing clinical development projects and studies in the pipeline in close collaboration with renowned researchers and institutions around the world. The company was founded in 2001 and is now headquartered in Oslo, Norway with an operating subsidiary in Lund, Sweden. Smartfish's main shareholders include Investinor (a Norwegian-based fund) and Industrifonden (a Nordic fund). Learn more on www.smartfishnutrition.com.
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: [email protected]
Stephanie Liu Tel: (852) 2864 4852 Email: [email protected]
Tika Lum Tel: (852) 2864 4806 Email: [email protected]
Fax: (852) 2527 1196
About Jacobson Pharma Corporation Limited
Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012 according to Frost & Sullivan. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Chai Kung Tji Thung San, Contractubex Scar Gel Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet are widely carried in the market. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, HealthCare
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
TOYOTA GAZOO Racing WRC Challenge Program
Jul 10, 2020 17:22 JST
Hitachi ABB Power Grids India Wins INR 120 Crore Order for Indian Railways Electrification
Jul 10, 2020 09:07 JST
NEC Solution Innovators Establishes "FonesLife," a healthcare business company that contributes to extending healthy life expectancy
Jul 09, 2020 14:34 JST
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 12:20 JST
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 12:11 JST
"Corolla Meets SUV"--Toyota Unveils Corolla Cross in Thailand, The New Compact SUV with Strength and Functionality to the Corolla Series
Jul 09, 2020 10:59 JST
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 14:33 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 14:16 JST
HSPP Announces Corporate Name Change to Honda India Power Products Limited
Jul 07, 2020 14:37 JST
Lexus Premieres New LS
Jul 07, 2020 13:31 JST
HOYA and Hitachi Announce Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
Jul 06, 2020 17:39 JST
Announcement of Absorption-type Merger (Simplified Merger and Short-form Merger) of DENSO IT Solutions Inc.
Jul 06, 2020 16:34 JST
JGA North is Ready for Service
Jul 06, 2020 15:30 JST
Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy
Jul 06, 2020 15:11 JST
Toyota Reproduces and Sells Spare Parts for 2000GT
Jul 06, 2020 13:37 JST
Fujitsu Embarks Towards 'New Normal', Redefining Working Styles for its Japan Offices
Jul 06, 2020 11:47 JST
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
Jul 06, 2020 09:33 JST
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
Jul 06, 2020 09:05 JST
NEC and JAMSTEC Develop AI-based System for Measuring Microplastics in the Ocean
Jul 03, 2020 11:30 JST
Fujitsu Revamps Corporate Philosophy 'FUJITSU Way' to Achieve Our Purpose
Jul 01, 2020 14:22 JST